Genprex Inc Stock Price, News & Analysis

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has issued a stockholder letter highlighting its progress in oncology and diabetes programs. Under the leadership of CEO Ryan Confer, the company reports significant advancements in its clinical development initiatives, particularly in two ongoing lung cancer trials.

The company emphasizes its commitment to developing novel gene therapies for cancer and diabetes patients, with multiple milestones expected in the second half of 2025. Genprex maintains its focus on streamlined strategies to build company-wide value while advancing its clinical programs.

Genprex (NASDAQ: GNPX) presented positive preclinical research results for GPX-002, its diabetes gene therapy drug candidate, at the 2025 American Diabetes Association Scientific Sessions. The therapy demonstrated promising results in non-human primates (NHPs) with streptozotocin-induced diabetes.

The research showed that GPX-002, which uses recombinant adeno-associated virus (rAAV) to deliver Pdx1 and MafA genes, successfully converted alpha cells into insulin-secreting beta-like cells. The treated NHPs showed improved glucose tolerance and reduced insulin requirements one month post-infusion. Temporary immunosuppression for 3 months proved effective in preventing anti-viral immunity, with researchers now evaluating a 6-month immunosuppression period.

Genprex (NASDAQ: GNPX) presented positive preclinical data for GPX-002, their diabetes gene therapy candidate, at the 2025 ADA Scientific Sessions. The research showcased a novel non-viral lipid nanoparticle (LNP) delivery system for diabetes gene therapy, demonstrating successful transfection of pancreatic cells through biliary duct infusion. Two specific LNPs showed high efficiency in transfecting α- and β-cells in mouse Islets of Langerhans, with the ALX-184 LNP achieving 100 times more luciferase activity in the pancreas compared to other organs. This breakthrough approach could enable repeat dosing without requiring immunosuppression, potentially offering advantages over traditional AAV delivery methods in treating Type 1 Diabetes.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in the BIO 2025 International Convention from June 16-19, 2025, in Boston. Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will represent the company and conduct one-on-one meetings with industry groups to discuss Genprex's gene therapies for cancer and diabetes. The BIO International Convention is the largest biotech event globally, attracting 20,000 industry leaders. Interested parties can schedule meetings through the conference portal or by contacting Investor Relations at investors@genprex.com.

Genprex (NASDAQ: GNPX) will present the trial design of its Acclaim-3 Phase 1/2 clinical trial at the 2025 ASCO Annual Meeting. The trial evaluates Reqorsa® Gene Therapy in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC). The study aims to improve the current median progression-free survival of 2.6 months in ES-SCLC patients. The trial's Phase 2 portion, which began enrollment in December 2024, will include 50 patients and targets a median PFS of approximately 4.3 months. The presentation will take place on May 31, 2025, featuring research showing that TUSC2, a tumor suppressor gene, is decreased in 100% of SCLC patients and absent in 41% of cases. Preclinical studies demonstrated that the Reqorsa-Tecentriq combination significantly increased tumor cell killing compared to Tecentriq alone.

Genprex (NASDAQ: GNPX) presented positive preclinical data for GPX-002, its diabetes gene therapy drug candidate, at the ASGCT 28th Annual Meeting. The therapy uses recombinant adeno-associated virus (rAAV) to deliver Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells. Studies in Non-Human Primates (NHPs) showed that one month post-infusion, subjects demonstrated improved glucose tolerance and reduced insulin requirements. The research revealed that temporary immunosuppression using rituximab, rapamycin, and steroids effectively prevents anti-viral immunity, though longer immunosuppression may be needed. The company continues preclinical studies in both Type 1 and Type 2 diabetes NHP models, evaluating viral efficacy after six months of immunosuppression.

Genprex (NASDAQ: GNPX) has signed a new Sponsored Research Agreement (SRA) with the University of Pittsburgh to study GPX-002, its gene therapy treatment for Type 1 (T1D) and Type 2 diabetes (T2D) in animal models. Previous preclinical data showed statistically significant improvements in insulin requirements, c-peptide levels, and glucose tolerance. GPX-002 uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. In T1D, it transforms alpha cells into functional beta-like cells that produce insulin while potentially evading immune response. For T2D, the therapy aims to rejuvenate exhausted beta cells. The treatment can be administered in humans through routine endoscopy.

Genprex (NASDAQ: GNPX) has secured an exclusive patent license agreement with UTHealth Houston for its lead drug candidate, Reqorsa® Gene Therapy, targeting glioblastoma treatment. The agreement grants Genprex exclusive commercial rights and patent exclusivity for using REQORSA in treating glioblastoma, the most aggressive and common primary brain tumor in adults. The company previously reported positive preclinical data in October 2024, where researchers observed that REQORSA significantly reduced glioblastoma cell viability and suppressed cell migration. The treatment works by restoring TUSC2 expression, which has been identified as a novel tumor suppressor for glioblastoma. These promising in vitro results support further evaluation using mouse models.

Genprex announced positive preclinical data for their Reqorsa® Gene Therapy in treating Ras inhibitor resistant lung cancer at the 2025 AACR Annual Meeting in Chicago. The research focused on treating KRASG12C mutant non-small cell lung cancer (NSCLC).

Key findings showed that Reqorsa effectively overcomes resistance to LUMAKRAS® (sotorasib) in NSCLC mouse models. The therapy demonstrated significant results both alone and in combination with sotorasib:

• Reduced colony formation and increased cancer cell death in resistant cell lines
• Decreased viability of resistant organoids
• Showed strong anti-tumor effects in controlling tumor growth
• Achieved synergistic anti-tumor effects when combined with sotorasib

The research suggests Reqorsa's potential as a treatment for Ras inhibitor resistant lung cancer, either as a standalone therapy or in combination with Ras inhibitors.